Clinical Trial Update: A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects [Phase 1]

View source ↗

Summary

This is a Phase I study assessing safety and immunogenicity of the UBI Multivalent HIV-1 Peptide Immunogen in HIV-seronegative adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• UBI Multivalent HIV-1 Peptide Immunogen

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED